ASX Healthcare Stocks Offering Investment Opportunity in November

The healthcare sector is buzzing with innovation as these companies continue to transform lives and are now well placed for investors to consider investing in to capture the potential upside.

Pro Medicus Limited (ASX: PME)

is strengthening its position in enterprise imaging and radiology software following another record-breaking year and a series of contracts.

The company delivered phenomenal financial results in FY25 as revenue grew by 31.9% to $213 million, profit after tax rose 39.2% to $115.2 million and ended the year with $210.7 million in cash and investments.

PME expanded into Europe recently by signing a five-year, $10 million deal with University Hospital Heidelberg and the German Cancer Research Institute to replace three legacy PACS systems.

The company’s total forward revenue now exceeds $948 million over five years supported by a great pipeline across the US and Europe.

ResMed Inc. (ASX: RMD)

has got a good start to FY26 as net revenue for the September quarter was US$1.34 billion which is a 9% growth from the same period last year while earnings per share rose to US$2.37 from US$2.11.

The Sleep and Breathing Health segment remained the backbone of ResMed’s performance as it generated revenue of US$1.17 billion which is a growth of 10% driven by higher demand across all major regions.

ResMed’s focus on technology-driven healthcare is proving to be a key advantage and the company’s software solutions help doctors track patient compliance and outcomes which reduces hospital visits.

With rising awareness about sleep disorders and the growing need for digital healthcare solutions, ResMed’s outlook remains positive and presents an opportunity for investors to capture the upside.

CSL Limited (ASX: CSL)

is one of the most established names in global healthcare and biotechnology although its share price has dipped recently, the company remains fundamentally sound.

CSL reported total revenue of US$15.56 billion for FY25 which is a growth of 5% and net profit after tax of US$3.09 billion, representing a 17 % rise from the previous year.

Earnings per share increased 10 % to US$6.65 while free cash flow rose 58 percent to US$2.86 billion and the company distributed a dividend of US$2.92 per share which is 11 % higher than last year.

CSL also revealed its plan to demerge CSL Seqirus into a separate ASX-listed vaccine company by the end of FY26.
With the help of diversified revenue streams and upcoming structural changes, the company is well positioned to deliver sustainable growth and value for long-term investors.

Mesoblast Limited (ASX: MSB)

is getting attention in the biotech and healthcare space as its lead product is gaining commercial traction.

Ryoncil which treats children under 12 suffering from steroid-refractory acute graft-versus-host disease (SR-aGvHD), is the first FDA-approved mesenchymal stromal cell therapy and remains the only product of its kind in this category.

For the three months ended September 2025, revenue from cell therapy products rose to US$20.6 million which is up from US$12.9 million in the June quarter and this jump was largely driven by a 69 % increase in Ryoncil net revenues.

Mesoblast is also developing new therapies by targeting heart failure and chronic lower back pain which are two major areas of unmet medical need.

Mesoblast ended the quarter with US$145 million in cash and the company also entered into a convertible note arrangement to raise up to US$50 million, which will be used to reduce existing loans and support ongoing development programs.

(Source: Company Reports)